ClinicalTrials.gg
CompletedNCT05662059Updated Oct 22, 2026

Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Study in Ulcerative Colitis

An interventional study of RAVANS and RAVANS-sham in Ulcerative Colitis, sponsored by Cala Health, Inc.. Completed at 1 site in United States. Open to participants aged 10 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Cala Health, Inc. · Not applicable, Interventional, and Other

How we know

Updated Oct 22, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
10 Years to 39 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 615 studies in Colitis, Ulcerative with a site in United States — 115 open to participants now, 167 under way, 34 of them phase 3. Colitis, Ulcerative · United States.

Enrollment
354th of 499
30 · median 76
Started
2023
with 34 others
No phase
103 of 615
25 open now
Registered
479th of 615
by date

Among the 615 studies in Colitis, Ulcerative with a site in United States, this one is the 354th largest by enrollment of the 499 interventional ones that give a count, is one of 35 that started in 2023, is one of 103 with no phase, and was the 479th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

115 of the 615 studies in Colitis, Ulcerative with a site in United States are open now. Recruiting first, the newest first:

110 more — sign in →

All 115 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 10 Years to 39 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 615 studies in Colitis, Ulcerative with a site in United States, or all of them as a file.
02

Study summary

Prospective, single-center, sham-controlled, double-blinded 12-week study designed to evaluate the safety and efficacy of the RAVANS device in subjects with Ulcerative Colitis. The goal of the study is to distinguish sham (no stimulation) versus treatment (stimulation) response and to identify treatment responders. The study will last 12 weeks with in-clinic visits at 0 weeks and 12 weeks, and a telehealth-visit at week 6. Additionally, unscheduled visits may occur based on the needs of the subject or at the discretion of the investigator. Subjects will be randomized 2:1 to treatment or sham, and will stimulate at home twice per day.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 22, 2026. See what changed

Ages eligible
10 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 10-39 years
  2. UC diagnosis for at least 3 months, confirmed by standard diagnostic evaluations including clinical, biochemical, and endoscopic studies
  3. If age 17 years or younger, a PUCAI score of 10-60
  4. A modification of UCDAI score of 3-6
  5. If on , the dose must be stable and ≤ 10mg/day (prednisone or equivalent) for at least 14 days before entry into study
  6. If on 5-Aminosalicylate, dose must be stable with following parameters:

    • 28 days on oral medication
    • 28 days on or off rectal medication
  7. If on background treatment the dose must be stable with the following parameters:

    • 56 days (8 weeks) for Immunomodulators (methotrexate, 6-MP, Azathioprine)
    • 112 days (16 weeks) for Infliximab, Adalimumab, Vedolizumab, Ustekinumab, other biologic, tofacitinib, upadacitinib, ozanimod
  8. Able and willing to give written and comply with the requirements of the study protocol.
  9. The earbud electrode must fit properly in the prospective subject's left ear
  10. Fecal calprotectin of ≥150 during screening period

Exclusion criteria

Exclusion Criteria:

  1. Expectation to increase and/or treatment
  2. Presence of bowel stricture
  3. History of intra-abdominal or perirectal abscess
  4. Disease limited to only rectum (ulcerative proctitis)
  5. Antibiotic treatment for active infection
  6. Presence of active intestinal infection or documented infection by stool PCR or culture analysis in the previous 6 weeks
  7. Continuous treatment with an anticholinergic medication, including over the counter medications (See appendix)
  8. Implantable electronic devices such as pacemakers, defibrillators, hearing aids, cochlear implants or deep brain stimulators.
  9. Current tobacco or nicotine user including nicotine patches, gum and vaping (to limit potential confounding effects of exposure to nicotine)
  10. Bowel resection surgery within past 90 days prior to study enrollment, or planned surgery within the course of the study
  11. Any planned surgical procedure requiring general anesthesia within the course of the study
  12. Participation in any other drug and/or treatment currently or planned during the length of the study
  13. Any condition which, in the opinion of the investigator, would jeopardize the subject's safety following exposure to a study intervention
  14. Pregnancy or Lactation
  15. Comorbid disease with high likelihood of requiring corticosteroid use
  16. Inability to comply with study and follow-up procedures
  17. Individuals with prior medical history of significant arrhythmias, including but not limited to, atrial fibrillation, atrial flutter, sick sinus syndrome, and AV blocks
  18. Individuals with existing skin lesions on the left ear
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Treatment

    Two therapy sessions (active stimulation) per day for 12 weeks with Treatment device

    Device: RAVANS

  • Sham comparator
    Sham

    Two therapy sessions per day for 12 weeks with Sham device (no active stimulation)

    Device: RAVANS-sham

Interventions

  • DeviceRAVANS

    Respiratory-Gated Auricular Vagal Afferent Nerve Stimulation

  • DeviceRAVANS-sham

    RAVANS sham device

06

What researchers measure

Primary outcomes

  1. Clinical Remission

    Remission rate in treatment vs sham, assessed by a 0 or 1 point score in the modification of ulcerative colitis disease activity index (UCDAI) Score at week 12

    Time frame: 12 weeks

Secondary outcomes

  1. Clinical Responder

    Responder rate in treatment vs sham, assessed by greater than or equal to a 2 point reduction in the modification of UCDAI Score between 0 and 12 weeks

    Time frame: 12 weeks

07

Study locations

1 site
  • Feinstein Institute for Medical Research at Northwell Health
    Lake Success, New York 11042, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Apr 2026, 39 months.

Of 239 interventional studies with no phase under Colitis, Ulcerative, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's 39 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Dec 2023 → Apr 2026 and completion Dec 2023 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2022
First posted
Dec 22, 2022
StartActual
Jan 12, 2023
Primary completionActual
Apr 15, 2026was Dec 2023
CompletionActual
Apr 15, 2026was Dec 2023
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 22, 2026
Primary completion
Dec 30, 2023→Apr 15, 2026 (actual)
Oct 22, 2026
Study completion
Dec 30, 2023→Apr 15, 2026 (actual)
Oct 22, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedA partial Mayomodification of UCDAI score of 3-6
Exclusion criteria
  • RemovedActive treatment with antibiotics
  • AddedAntibiotic treatment for active infection
Oct 22, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionClinical Remission: how it is measured was reworded
Oct 22, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionClinical Responder: how it is measured was reworded
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Status unknown→Completed
    Primary completion Dec 30, 2023→Apr 15, 2026 (now actual)
    Study completion Dec 30, 2023→Apr 15, 2026 (now actual)
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedA partial Mayomodification of UCDAI score of 3-6
    Exclusion criteria
    • RemovedActive treatment with antibiotics
    • AddedAntibiotic treatment for active infection
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionClinical Remission: how it is measured was reworded
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionClinical Responder: how it is measured was reworded
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05662059
Lead sponsor
Cala Health, Inc.
Responsible party
Sponsor
First posted
Dec 22, 2022
Start date
Jan 12, 2023
Primary completion
Apr 15, 2026
Completion
Apr 15, 2026
Last update
Oct 22, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion